Pterostilbene

BIOLOGICAL2 trials

Sponsors

City of Hope Medical Center, University of Colorado, Denver

Conditions

Atypical Endometrial HyperplasiaClonal Cytopenia of Undetermined SignificanceEndometrial CarcinomaMyelodysplastic Syndrome

Phase 2

Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy

Active, not recruitingNCT03671811

City of Hope Medical CenterAtypical Endometrial Hyperplasia, Endometrial Carcinoma

Start: 2019-01-21End: 2027-02-28Updated: 2026-06-03

Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial)

RecruitingNCT07579429

University of Colorado, DenverClonal Cytopenia of Undetermined Significance, Myelodysplastic Syndrome

Start: 2026-05-20End: 2030-12-18Target: 10Updated: 2026-06-03

Related Papers

Pterostilbene as a Multifaceted Anticancer Agent: Molecular Mechanisms, Therapeutic Potential and Future Directions.

2025-05-24

The Anti-Cancer Role of Pterostilbene in Endometrial Cancer: A Phase II Prospective, Randomized, Window-of-Opportunity Clinical Trial with Megestrol Acetate

Antioxidants2025-03-144 citations

Differential gene expression analysis of a phase II randomized clinical trial of patients with endometrial cancer (EC) treated with megestrol acetate ± pterostilbene.

Journal of Clinical Oncology2024-06-012 citations

The effect of megestrol acetate ± pterostilbene in endometrial cancer: A prospective, randomized, window-of-opportunity clinical trial.

Journal of Clinical Oncology2023-06-01